Wuhan Wuyao Pharmaceutical is an API manufacturer based in China. It holds 12 valid CEPs across a filed portfolio of 11 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 7 March 2025 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Huangshi City, China | Not on file |
| Huangshi, China | Not on file |
| China, China | 3010686159 |
| Molecule | Regulators | Docs |
|---|---|---|
| Norepinephrine | EDQM, SFDA (Saudi Arabia) | 3 |
| Epinephrine | EDQM | 2 |
| Metronidazole | EDQM | 2 |
| Dopamine | EDQM | 1 |
| Hydroxychloroquine | EDQM | 1 |
| Isoprenaline | EDQM | 1 |
| Metamizole | EDQM | 1 |
| Norepinephrine Bitartrate | SFDA (Saudi Arabia) | 1 |
| Phenylephrine | EDQM | 1 |
| Trimetazidine Dihydrochloride | EDQM | 1 |
| Xylometazoline | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
| EMA | None | 1 |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Ask Fred what the record holds on Wuhan Wuyao Pharmaceutical, including filings and inspection history.
Chat with Fred, your AI analystRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.